

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peng Cho TANG et al.
Title: BICYCLIC PROTEIN KINASE INHIBITORS
Prior Appl. No.: 09/819,698
Prior Appl. Filing Date: 03/29/2001
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/819,698, filed 03/29/2001, which is a divisional of application Serial No. 09/074,621, filed 05/07/1998. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent applications.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE


The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 12/2/03

By 

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/819,698
				Filing Date	03/29/2001
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0906
Sheet	1	of	14		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	Re. 36,256	E	Spada et al.	07-20-1999	
	A2	4,002,749		Rovnyak	01-11-1977	
	A3	4,053,613		Rovnyak et al.	10-11-1977	
	A4	4,966,849		Vallee et al.	10-30-1990	
	A5	5,196,446	A	Levitzi et al.	03-23-1993	
	A6	5,217,999	A	Levitzi et al.	06-08-1993	
	A7	5,302,606	A	Spada et al.	04-12-1994	
	A8	5,322,950	A	Sircar et al.	06-21-1994	
	A9	5,330,992	A	Eissenstat et al.	07-19-1994	
	A10	5,397,787	A	Buzzetti et al.	03-14-1995	
	A11	5,786,488	A	Tang et al.	07-28-1998	
	A12	5,792,783	A	Tang et al.	08-11-1998	
	A13	5,880,141	A	Tang et al.	03-09-1999	
	A14	5,883,113	A	Tang et al.	03-16-1999	
	A15	5,883,116	A	Tang et al.	03-16-1999	
	A16	5,886,020	A	Tang et al.	03-23-1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <i>(use as many sheets as necessary)</i>				Complete if Known Application Number 09/819,698 Filing Date 03/29/2001 First Named Inventor Peng Cho TANG Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 034536-0906	
Sheet	2	of	14		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A17	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
	A18	WO	91/15495	A1	PFIZER INC.	10-17-1991		
	A19	WO	92/07830	A2	PFIZER INC.	05-14-1992		
	A20	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
	A21	WO	92/21660	A1	PFIZER INC.	12-10-1992		
	A22	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993		
	A23	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
	A24	WO	94/10202	A1	GENENTECH, INC.	05-11-1994		
	A25	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
	A26	WO	95/14667	A1	PFIZER INC.	06-01-1995		
	A27	WO	95/24190	A2	SUGEN, INC.	09-14-1995		
	A28	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
	A29	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
	A30	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
	A31	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
	A32	WO	98/07695	A1	SUGEN, INC.	02-26-1998		
	A33	WO	98/07835	A2	SUGEN, INC.	02-26-1998		
	A34	WO	98/45708	A1	SUGEN, INC.	10-15-1998		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number				09/819,698	
Filing Date				03/29/2001	
First Named Inventor				Peng Cho TANG	
Group Art Unit				Unassigned	
Examiner Name				Unassigned	
Attorney Docket Number				034536-0906	
Sheet	3	of	14		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴ Kind Code ⁵ (if known)			
	A35	WO	98/50356	A1	SUGEN, INC.	11-12-1998
	A36	WO	98/56376	A1	SUGEN, INC.	12-17-1998
	A37	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999
	A38	EP	0 252 713	B1	PFIZER INC.	01-13-1988
	A39	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993
	A40	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965
	A41	HU	3899/92		RICHTER GEDEON VEGYESZETI GYAR RT	12-10-1992

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A42	AKBASAK and SUNAR-AKBASAK, "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)© Elsevier Science Publishers		
	A43	ANDREANI et al., "Synthesis and potential coanthracryclinc activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997)© Elsevier, Paris		
	A44	ANDREANI et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48:727-729 (1998) ©		
	A45	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/819,698
Date Submitted:		Filing Date	03/29/2001
(use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	4 of 14	Attorney Docket Number	034536-0906

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	A46	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994) © The American Society for Microbiology	
	A47	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994) © Cell Press	
	A48	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)	
	A49	Beilstein Reg. No. 252929 (1998)	
	A50	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)	
	A51	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) copyright MacMillan Press Ltd.	
	A52	BONNER et al., "Structure and Biological Activity of Human Homologs of the <i>rat/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) © The American Society for Microbiology	
	A53	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)	
	A54	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) © Wiley-Liss, Inc.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/819,698
Date Submitted:		Filing Date	03/29/2001
(use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	5 of 14	Attorney Docket Number	034536-0906

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A55	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997) © Academic Press, Inc.	
	A56	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40:149-156 (1997)	
	A57	CLAESSON-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) © Elsevier Science Ltd.	
	A58	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) © The American Society for Microbiology	
	A59	DAMIANI et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48:1155-1161 (1994) copyright Elsevier Science Ltd.	
	A60	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16:1043-1045 (1973) © American Chemical Society	
	A61	DE VRIES et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)	
	A62	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) copyright Elsevier	
	A63	DICKSON et al., "13. Tyrosine kinase receptor - nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) © Kluwer Academic Publishers	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <i>(use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td>Application Number</td><td>09/819,698</td></tr> <tr><td>Filing Date</td><td>03/29/2001</td></tr> <tr><td>First Named Inventor</td><td>Peng Cho TANG</td></tr> <tr><td>Group Art Unit</td><td>Unassigned</td></tr> <tr><td>Examiner Name</td><td>Unassigned</td></tr> <tr><td>Attorney Docket Number</td><td>034536-0906</td></tr> </table>		Application Number	09/819,698	Filing Date	03/29/2001	First Named Inventor	Peng Cho TANG	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	034536-0906
Application Number	09/819,698														
Filing Date	03/29/2001														
First Named Inventor	Peng Cho TANG														
Group Art Unit	Unassigned														
Examiner Name	Unassigned														
Attorney Docket Number	034536-0906														
Sheet	6	of	14												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A64	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) © Cell Press	
	A65	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product," <u>Cancer Research</u> 50:1550-1558 (1990); © American Association for Cancer Research	
	A66	FERRARA and HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) © Academic Press, Inc.	
	A67	FINGL and WOODBURY, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) © MacMillan Publishing Co. Inc.	
	A68	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) © International Society of Nephrology	
	A69	FOLKMAN and SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology	
	A70	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)	
	A71	FOLKMAN, "Tumor Angiogenesis: Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)	
	A72	FOLKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/819,698
Date Submitted:		Filing Date	03/29/2001
(use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	7 of 14	Attorney Docket Number	034536-0906

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A73	GAZIT et al., "Tyrosinostins. 2. Heterocyclic and α -Substituted Benzyldienemalononitrile Tyrosinostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) copyright Am. Chem. Soc.	
	A74	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)	
	A75	GOLDRING and GOLDRING, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)	
	A76	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268:9165-9168 (1993) ©American Society for Biochemistry and Molecular Biology	
	A77	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) © Cell Press	
	A78	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992) © American Society for Biochemistry and Molecular Biology, Inc.	
	A79	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12:981-990 (1992) copyright Am. Soc. Microbiol.	
	A80	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994) © American Chemical Society	
	A81	KASHISHIAN and COOPER, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C γ 1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993) © The American Society for Cell Biology	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

² Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/819,698
Date Submitted:		Filing Date	03/29/2001
(use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	8 of 14	Attorney Docket Number	034536-0906

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A82	KASHISHIAN et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11:1373-1382 (1992)	
	A83	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993) ©Elsevier Science	
	A84	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
	A85	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
	A86	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)	
	A87	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992) © Academic Press, Inc.	
	A88	KLASBRUN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993) ©Current Biology	
	A89	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)	
	A90	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

² Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <i>(use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/819,698</td> </tr> <tr> <td>Filing Date</td> <td>03/29/2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Pang Cho TANG</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>034536-0906</td> </tr> </table>		Application Number	09/819,698	Filing Date	03/29/2001	First Named Inventor	Pang Cho TANG	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	034536-0906
Application Number	09/819,698														
Filing Date	03/29/2001														
First Named Inventor	Pang Cho TANG														
Group Art Unit	Unassigned														
Examiner Name	Unassigned														
Attorney Docket Number	034536-0906														
Sheet	9	of	14												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A91	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.	
	A92	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) © Elsevier Science Publishers	
	A93	KUMABE et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)	
	A94	LEE and DONOGHUE, "Intracellular Retention of Membrane-Anchored v-sis Protein Abrogates Autocrine Signal T transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992) ©The Rockefeller University Press	
	A95	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)	
	A96	MAASS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37:2612-2617 (1993) ©American Society for Microbiology	
	A97	MACAULAY et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," <u>Cancer Research</u> 50:2511-2517 (1990)	
	A98	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)	
	A99	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) © Cell Press	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	09/819,698
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-0906
Sheet	10	of	14

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A100	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) © American Association for the Advancement of Science	
	A101	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) ©North-Holland Publishing Company	
	A102	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29:1561-1564 (1979)	
	A103	MORRISON et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)	
	A104	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) copyright Elsevier Publishers B.V.	
	A105	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)	
	A106	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7:334-339 (1994)	
	A107	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)	
	A108	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.² Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Complete If Known Application Number 09/819,698 Filing Date 03/29/2001 First Named Inventor Peng Cho TANG Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 034536-0906	
Sheet	11	of	14

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A109	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969)	
	A110	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)	
	A111	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) © Cell Press	
	A112	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990)	
	A113	SHIRAIISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987) © Academic Press	
	A114	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena	
	A115	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4'-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)	
	A116	SINKULA, "Prodrug Approach in Drug Design," <u>Medicinal Chemistry</u> , Vol. 10, pp. 306-315, 1975, © Academic Press	
	A117	SLAMON et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	09/819,698
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-0906
Sheet	12	of	14

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A118	SOLDI et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13:515-525 (1996) copyright Stockton Press	
	A119	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) © Cell Press	
	A120	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/les, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) © American Society for Microbiology	
	A121	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) ©Ashley Publications	
	A122	SUN et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) ©The American Chemical Society	
	A123	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech.</u> 14:600-605 (1996)	
	A124	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) © Oxford University Press	
	A125	TAKANO et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)	
	A126	TORP et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>APMIS</u> 100:713-719 (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	09/819,698
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-0906
Sheet	13	of	14

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A127	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) © Ashley Publications Ltd.	
	A128	TROST et al. (ed.), <u>Comprehensive Organic Synthesis, Selectivity, Strategy & Efficiency in Modern Organic Chemistry</u> , 4:477-480 (1991), Elsevier Science Ltd.	
	A129	TSAI et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31:943-947 (1992) ©Pergamon Press	
	A130	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)	
	A131	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci. USA</u> 90:7696-7700 (1993)	
	A132	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) © The American Society for Biochemistry and Molecular Biology	
	A133	VARMA and GUPTA, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) © The Indian Chemical Society	
	A134	VOLLER et al., "Ch. 45 – Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980); © American Society for Microbiology	
	A135	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Complete if Known	
		Application Number	09/819,698
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
Attorney Docket Number	034536-0906		
Sheet	14	of	14

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A136	WEIDNER et al., "Tumor Angiogenesis and Metastasis – Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) © Massachusetts Medical Society	
	A137	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	
	A138	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57:57-64 (1999) ©Elsevier Science Inc.	
	A139	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) ©The American Society for Pharmacology and Experimental Pharmaceutics	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.